Updated Thursday, June 27, 2019
 Journal Tools
RSS Feed
Sample Copy
Submit a Manuscript
Contact Us
Thanking Peer Reviewers
 Language Polishing
Journal of Integrative Medicine: Volume 13, 2015   Issue 4,  Pages: 231–240

DOI: 10.1016/S2095-4964(15)60176-5
Systematic Review
A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes
1. Heather Ann Hausenblas (Department of Kinesiology, Jacksonville University, Jacksonville, Florida 32211, USA )
2. Kacey Heekin (Department of Aging & Geriatric Research, University of Florida, Gainesville, Florida 32611, USA )
3. Heather Lee Mutchie (Department of Aging & Geriatric Research, University of Florida, Gainesville, Florida 32611, USA )
4. Stephen Anton (Department of Aging & Geriatric Research, University of Florida, Gainesville, Florida 32611, USA )


BACKGROUND: Throughout the past three decades, increased scientific attention has been given to examining saffron’s (Crocus sativus L.) use as a potential therapeutic or preventive agent for a number of health conditions, including cancer, cardiovascular disease, and depression.

OBJECTIVE: The purpose of this systematic review is to examine and categorize the current state of scientific evidence from randomized controlled trials (RCTs) regarding the efficacy of saffron on psychological/behavioral outcomes.

SEARCH STRATEGY: Electronic and non-electronic systematic searches were conducted to identify all relevant human clinical research on saffron. The search strategy was extensive and was designed according to the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).” Reference lists of articles that met the inclusion criteria were searched. Only English language studies were reviewed.

INCLUSION CRITERIA: Saffron trials in combination with other substances and saffron safety studies were considered, in accordance with the PRISMA statement. Included studies must have a control group. Included studies must measure a physiological and/or a behavioral outcome.

DATA EXTRACTION AND ANALYSIS: The methodological quality of all included studies was independently evaluated by two reviewers using the Jadad score. Mean scores and P-values of measures were compared both inter- and intra-study for each parameter (i.e., depression).

RESULTS: Twelve studies met our inclusion criteria. These studies examined the effects of saffron on psychological/behavioral outcomes of: major depressive disorder (n = 6), premenstrual syndrome (n = 1), sexual dysfunction and infertility (n = 4), and weight loss/snacking behaviors (n = 1). The data from these studies support the efficacy of saffron as compared to placebo in improving the following conditions: depressive symptoms (compared to anti-depressants and placebo), premenstrual symptoms, and sexual dysfunction. In addition, saffron use was also effective in reducing excessive snacking behavior.

CONCLUSION: Findings from initial clinical trials suggest that saffron may improve the symptoms and the effects of depression, premenstrual syndrome, sexual dysfunction and infertility, and excessive snacking behaviors. Larger multi-site clinical trials are needed to extend these preliminary findings.

Welcome to JIM! You are the number 7630 reader of this article!
Download Article:
[Full Text]      [PDF]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Hausenblas HA, Heekin K, Mutchie HL, Anton S. A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes. J Integr Med. 2015; 13(4): 231–240.
1Capasso F, Gaginella TS, Grandolini G, Izzo AA. Phytotherapy: a quick reference to herbal medicine. Berlin: Spriger-Verlag. 2003.
2Williamson EM, Okpako DT, Evans FJ. Pharmacological methods in phytotherapy. John Wiley & Sons. 1996.
3Gohari AR, Saeidnia S, Mahmoodabadi MK. An overview on saffron, phytochemicals, and medicinal properties[J].Pharmacogn Rev, 2013, 7(13): 61–66.  
4Moghaddasi MS. Saffron chemicals and medicine usage[J].J Med Plants Res, 2010, 4: 427–430.  
5Srivastava R, Ahmed H, Dixit RK, Dharamveer, Saraf S. Crocus sativus L.: A comprehensive review[J].Pharmacogn Rev, 2010, 4(8): 200–208.  
6Kianbakht S, Ghazavi A. Immunomodulatory effects of saffron: a randomized double-blind placebo-controlled clinical trial[J].Phytother Res, 2011, 25(12): 1801–1805.  
7Abdullaev FI, Espinosa-Aguirre JJ. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials[J].Cancer Detect Prev, 2004, 28(6): 426–432.  
8Bathaie SZ, Mousavi SZ. New applications and mechanisms of action of saffron and its important ingredients[J].Crit Rev Food Sci Nutr, 2010, 50(8): 761–786.  
9Kamalipour M, Akhondzadeh S. Cardiovascular effects of saffron: an evidence-based review[J].J Tehran Heart Cent, 2011, 6(2): 59–61.  
10Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials[J]. J Integr Med, 2013, 11(6): 377–383.  
11Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action[J].Hum Psychopharmacol, 2014, 29(6): 517–527.  
12Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J].Ann Intern Med, 2009, 151(4): 264–269.  
13Ulbricht C, Conquer J, Costa D, Hollands W, Iannuzzi C, Isaac R, Jordan JK, Ledesma N, Ostroff C, Serrano JM, Shaffer MD, Varghese M. An evidence-based systematic review of saffron (Crocus sativus) by the Natural Standard Research Collaboration[J].J Diet Suppl, 2011, 8(1): 58–114.  
14Nahid K, Fariborz M, Ataolah G, Solokian S. The effect of an Iranian herbal drug on primary dysmenorrhea: a clinical controlled trial[J].J Midwifery Womens Health, 2009, 54(5): 401–404.  
15Modaghegh MH, Shahabian M, Esmaeili HA, Rajbai O, Hosseinzadeh H. Safety evaluation of saffron (Crocus sativus) tablets in healthy volunteers[J].Phytomedicine, 2008, 15(12): 1032–1037.  
16Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17(1): 1–12.
17Heidary M, Vahhabi S, Reza Nejadi J, Delfan B, Birjandi M, Kaviani H, Givrad S. Effect of saffron on semen parameters of infertile men[J].Urol J, 2008, 5(4): 255–259.  
18Akhondzadeh Basti A, Ghoreishi S, Noorbala AA, Akhondzadeh SH, Rezazadeh SH. Petal and stigma of Crocus sativus L. in the treatment of depression: a pilot double-blind randomized trial[J].J Med Plants, 2008, 7(4): 29–36.  
19Marangoni D, Falsini B, Piccardi M, Ambrosio L, Minnella AM, Savastano MC, Bisti S, Maccarone R, Fadda A, Mello E, Concolino P, Capoluongo E. Functional effect of saffron supplementation and risk genotypes in early age-related macular degeneration: A preliminary report[J].J Transl Med, 2013, 11: 228.  
20Piccardi M, Marangoni D, Minnella AM, Savastano MC, Valentini P, Ambrosio L, Capoluongo E, Maccarone R, Bisti S, Falsini B. A longitudinal follow-up study of saffron supplementation in early age-related macular degeneration: sustained benefits to central retinal function[J].Evid Based Complement Alternat Med, 2012, 2012: 429124.  
21Shamsa A, Hosseinzadeh H, Molaei M, Shakeri MT, Rajabi O. Evaluation of Crocus sativus L. (saffron) on male erectile dysfunction: a pilot study[J].Phytomedicine, 2009, 16(8): 690–693.  
22Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, Alimardani R, Jamshidi A, Rezazadeh SA, Yousefi A, Zare F, Moradi A, Vossoughi A. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease[J].Psychopharmacology (Berl), 2010, 207(4): 637–643.  
23Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A. Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial[J].J Clin Pharm Ther, 2010, 35(5): 581–588.  
24Ayatollahi H, Javan AO, Khajedaluee M, Shahroodian M, Hosseinzadeh H. Effect of Crocus sativus L. (saffron) on coagulation and anitcoagulation systems in healthy volunteers[J].Phytother Res, 2013, 28(4): 539–543.  
25Falsini B, Piccardi M, Minnella A, Savastano C, Capoluongo E, Fadda A, Balestrazzi E, Maccarone R, Bisti S. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration[J].Invest Ophthalmol Vis Sci, 2010, 51(12): 6118–6124.  
26Verma SK, Bordia A. Antioxidant property of saffron in man[J].Indian J Med Sci, 1998, 52(5): 205–207.  
27Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, Khani M. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial[J].Phytother Res, 2005, 19(2): 148–151.  
28Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial[J].Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31(2): 439–442.  
29Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin Abbasi S, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial[J].Phytomedicine, 2006, 13: 607–611.  
30Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial[J].J Ethnopharmacol, 2005, 97(2): 281–284.  
31Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816][J].BMC Complement Altern Med, 2004, 4: 12.  
32Shahmansouri N, Farokhnia M, Abbasi SH, Kassaian SE, Noorbala Tafti AA, Gougol A, Yekehtaz H, Forghani S, Mahmoodian M, Saroukhani S, Arjmandi-Beglar A, Akhondzadeh S. A randomized, double-blind, clinical trial comparing the efficacy and safety of Cocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients[J].J Affect Disord, 2014, 155: 216–222.  
33Modabbernia A, Sohrabi H, Nasehi AA, Raisi F, Saroukhani S, Jamshidi A, Tabrizi M, Ashrafi M, Akhondzadeh S. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial[J].Psychopharmacology (Berl), 2012, 223(4): 381–388.  
34Safarinejad MR, Shafiei N, Safarinejad S. A prospective double-blind randomized placebo-controlled study of the effect of saffron (Crocus sativus Linn.) on semen parameters and seminal plasma antioxidant capacity in infertile men with idiopathic oligoasthenoteratozoospermia[J].Phytother Res, 2011, 25(4): 508–516.  
35Safarinejad MR, Shafiei N, Safarinejad S. An open label, randomized, fixed-dose, crossover study comparing efficacy and safety of sildenafil citrate and saffron (Crocus sativus Linn.) for treating erectile dysfunction in men na?ve to treatment[J].Int J Impot Res, 2010, 22: 240–250.  
36Kashani L, Raisi F, Saroukhani S, Sohrabi H, Modabbernia A, Nasehi AA, Jamshidi A, Ashrafi M, Mansouri P, Ghaeli P, Akhondzadeh S. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study[J].Hum Psychopharmacol, 2013, 28(1): 54–60.  
37Agha-Hosseini M1, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, Akhondzadeh S. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial[J].BJOG, 2008, 115(4): 515–519.  
38Gout B, Bourges C, Paineau-Dubreuil S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women[J].Nutr Res, 2010, 30(5): 305–313.  
39Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence[J].Eur Neuropsychopharmacol, 2011, 21(12): 841–860.  
 Home | Current Issue | Past Issues | SearchRSS
Copyright © 2013-2018 by JIM Editorial Office. All rights reserved. ISSN 2095-4964; CN 31-2083/R. 沪ICP备110264号